Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Metastatic Castration Resistant Prostate Cancer Metastatic Cancer mCRPC Immunotherapy CDK12 Prostatic Neoplasms Neoplasm Metastasis Neoplasms Neoplasms, Second Primary Nivolumab Ipilimumab Metastatic CRPC Solid Tumors (non-prostate)
Lead Scientist at UCSD
- Rana McKay, M.D.
Associate Clinical Professor, Medicine. Authored (or co-authored) 128 research publications.
- accepting new patients
- Start Date
- Completion Date
- University of Michigan Rogel Cancer Center
- Phase 2
- Study Type
- Last Updated